BRC Inc. Class A BRCC 深 沪
交易中 11-10 10:35:22 美东时间
1.225
+0.005
+0.41%
华盛通- 最 高1.25
- 今 开1.24
- 成交量 7.78万股
- 最 低 1.2135
- 昨 收 1.22
- 总市值 1.40亿
- 52周最高 3.34
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.19
- 委 比 -27.27%
- 总股本 1.14亿
- 历史最高 34.00
- 量 比 0.75
- 振 幅 2.99%
- 历史最低 1.19
- 每 手 1
- 风险率 0.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRC FY2025 Revenue expected to be At least $395.000M vs $399.104M Est
BRC (NYSE:BRCC) FY2025 Revenue expected to be more than $395.000M vs $399.104M Est
11-04 05:19
BRC Q3 Sales $100.712M Miss $101.791M Estimate
BRC (NYSE:BRCC) reported quarterly sales of $100.712 million which missed the analyst consensus estimate of $101.791 million by 1.06 percent. This is a 2.55 percent increase over sales of $98.204 million the same period
11-04 05:17
Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
11-03 19:11
A Look at BRC's Upcoming Earnings Report
BRC (NYSE:BRCC) is preparing to release its quarterly earnings on Monday, 2025-...
11-01 05:02
美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
Telsey Advisory Group Maintains Outperform on BRC, Maintains $2.5 Price Target
Telsey Advisory Group analyst Sarang Vora maintains BRC (NYSE:BRCC) with a Outperform and maintains $2.5 price target.
10-27 18:36
BRC Expands Board, Appoints Melvin Landis
An update from BRC ( ($BRCC) ) is now available. On September 15, 2025, BRC Inc...
09-17 20:48
A Glimpse Into The Expert Outlook On BRC Through 4 Analysts
4 analysts have expressed a variety of opinions on BRC (NYSE:BRCC) over the pas...
08-07 02:04
Telsey Advisory Group Maintains Outperform on BRC, Maintains $4 Price Target
Telsey Advisory Group analyst Sarang Vora maintains BRC (NYSE:BRCC) with a Outperform and maintains $4 price target.
08-05 18:24
BRC Affirms FY2025 Sales Guidance of $395.000M-$425.000M vs $407.443M Est
BRC (NYSE:BRCC) affirms FY2025 sales outlook from $395.000 million-$425.000 million to $395.000 million-$425.000 million vs $407.443 million estimate.
08-05 04:17
